chr7-100271977-A-C
Position:
Variant summary
Our verdict is Likely benign. Variant got -2 ACMG points: 2P and 4B. PM2BP4_Strong
The ENST00000328453.9(CASTOR3P):n.230T>G variant causes a non coding transcript exon change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000915 in 1,573,890 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★).
Frequency
Genomes: 𝑓 0.000059 ( 0 hom., cov: 31)
Exomes 𝑓: 0.000095 ( 0 hom. )
Consequence
CASTOR3P
ENST00000328453.9 non_coding_transcript_exon
ENST00000328453.9 non_coding_transcript_exon
Scores
1
15
Clinical Significance
Conservation
PhyloP100: 0.398
Genes affected
CASTOR3P (HGNC:29954): (CASTOR family member 3, pseudogene) Predicted to be involved in cellular response to L-arginine and negative regulation of TORC1 signaling. Predicted to be active in cytosol. [provided by Alliance of Genome Resources, Apr 2022]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Likely_benign. Variant got -2 ACMG points.
PM2
Very rare variant in population databases, with high coverage;
BP4
Computational evidence support a benign effect (MetaRNN=0.012230486).
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
CASTOR3P | NR_028038.2 | n.229T>G | non_coding_transcript_exon_variant | 1/7 | ||||
CASTOR3P | NR_028039.1 | n.256T>G | non_coding_transcript_exon_variant | 1/8 | ||||
CASTOR3P | NR_028040.1 | n.256T>G | non_coding_transcript_exon_variant | 1/6 | ||||
CASTOR3P | NR_166147.1 | n.229T>G | non_coding_transcript_exon_variant | 1/5 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
CASTOR3P | ENST00000328453.9 | n.230T>G | non_coding_transcript_exon_variant | 1/8 | 1 | |||||
CASTOR3P | ENST00000414739.3 | n.238T>G | non_coding_transcript_exon_variant | 1/6 | 1 | |||||
CASTOR3P | ENST00000543273.5 | n.232T>G | non_coding_transcript_exon_variant | 1/6 | 1 |
Frequencies
GnomAD3 genomes AF: 0.0000594 AC: 9AN: 151448Hom.: 0 Cov.: 31
GnomAD3 genomes
AF:
AC:
9
AN:
151448
Hom.:
Cov.:
31
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.000101 AC: 21AN: 207538Hom.: 0 AF XY: 0.0000782 AC XY: 9AN XY: 115118
GnomAD3 exomes
AF:
AC:
21
AN:
207538
Hom.:
AF XY:
AC XY:
9
AN XY:
115118
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0000949 AC: 135AN: 1422334Hom.: 0 Cov.: 31 AF XY: 0.0000636 AC XY: 45AN XY: 708008
GnomAD4 exome
AF:
AC:
135
AN:
1422334
Hom.:
Cov.:
31
AF XY:
AC XY:
45
AN XY:
708008
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000594 AC: 9AN: 151556Hom.: 0 Cov.: 31 AF XY: 0.0000945 AC XY: 7AN XY: 74086
GnomAD4 genome
AF:
AC:
9
AN:
151556
Hom.:
Cov.:
31
AF XY:
AC XY:
7
AN XY:
74086
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
ExAC
AF:
AC:
10
ClinVar
Significance: Uncertain significance
Submissions summary: Uncertain:1
Revision: criteria provided, single submitter
LINK: link
Submissions by phenotype
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Feb 28, 2023 | The c.7T>G (p.C3G) alteration is located in exon 1 (coding exon 1) of the GATS gene. This alteration results from a T to G substitution at nucleotide position 7, causing the cysteine (C) at amino acid position 3 to be replaced by a glycine (G). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
BayesDel_addAF
Benign
T
BayesDel_noAF
Benign
CADD
Benign
DANN
Benign
DEOGEN2
Benign
T
Eigen
Benign
Eigen_PC
Benign
FATHMM_MKL
Benign
N
LIST_S2
Benign
T
M_CAP
Benign
T
MetaRNN
Benign
T
MetaSVM
Benign
T
PROVEAN
Benign
N
REVEL
Benign
Sift
Pathogenic
D
Polyphen
B
Vest4
MutPred
Gain of relative solvent accessibility (P = 0.0166);
MVP
MPC
ClinPred
T
GERP RS
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at